{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:29:44Z","timestamp":1783776584283,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Ataxia telangiectasia mutated and Rad3-related (ATR), a vital member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, plays a critical role in the DNA damage response (DDR). Tumor cells with a loss of DDR function or defects in the ataxia telangiectasia mutated (ATM) gene are generally more dependent on ATR for survival, suggesting that ATR is an attractive anticancer drug target based on its synthetic lethality. Herein, we present a potent and highly selective ATR inhibitor, ZH-12 (IC50 = 0.0068 \u03bcM). It showed potent antitumor activity as a single agent or in combination with cisplatin in the human colorectal adenocarcinoma LoVo tumor xenograft mouse model. Overall, ZH-12 may be a promising ATR inhibitor based on the principle of synthetic lethality and deserves further in-depth study.<\/jats:p>","DOI":"10.3390\/molecules28114521","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T08:50:31Z","timestamp":1685695831000},"page":"4521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer"],"prefix":"10.3390","volume":"28","author":[{"given":"Jialu","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Department of Pharmacology and Medicinal Chemistry, Jiangsu Vocational College of Medicine, Yancheng 224005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1002\/1878-0261.13224","article-title":"Resistance to DNA repair inhibitors in cancer","volume":"16","author":"Baxter","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"174957","DOI":"10.1016\/j.ejphar.2022.174957","article-title":"DNA damage response and repair in the development and treatment of brain tumors","volume":"924","author":"Sadoughi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00294-018-0817-9","article-title":"Branching the Tel2 pathway for exact fit on phosphatidylinositol 3-kinase-related kinases","volume":"64","author":"Sugimoto","year":"2018","journal-title":"Curr. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1881395","DOI":"10.1080\/23723556.2021.1881395","article-title":"It takes three to the DNA damage response tango","volume":"8","author":"Ziv","year":"2021","journal-title":"Mol. Cell Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.dnarep.2010.09.019","article-title":"A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation","volume":"9","author":"Dobbs","year":"2010","journal-title":"DNA Repair"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/febs.14145","article-title":"Hsp90alpha regulates ATM and NBN functions in sensing and repair of DNA double-strand breaks","volume":"284","author":"Pennisi","year":"2017","journal-title":"FEBS J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1093\/nar\/gkac472","article-title":"THO complex deficiency impairs DNA double-strand break repair via the RNA surveillance kinase SMG-1","volume":"50","author":"Kamp","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1080\/15548627.2020.1805860","article-title":"ATM loss disrupts the autophagy-lysosomal pathway","volume":"17","author":"Cheng","year":"2021","journal-title":"Autophagy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Marechal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Faulhaber, E.M., Jost, T., Symank, J., Scheper, J., Burkel, F., Fietkau, R., Hecht, M., and Distel, L.V. (2021). Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells. Genes, 12.","DOI":"10.3390\/genes12060925"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15167","DOI":"10.1073\/pnas.0504981102","article-title":"Drosophila ATM and ATR checkpoint kinases control partially redundant pathways for telomere maintenance","volume":"102","author":"Bi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","article-title":"Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models","volume":"63","author":"Lucking","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.30373","article-title":"Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells","volume":"140","author":"Kim","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally Designed PI3Kalpha Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114187","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","article-title":"Hallmarks of DNA replication stress","volume":"82","author":"Saxena","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41419-019-1689-8","article-title":"ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation","volume":"10","author":"Gomes","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1002\/jcp.30898","article-title":"ATM- and ATR-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma","volume":"237","author":"Chao","year":"2022","journal-title":"J. Cell. Physiol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/11\/4521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:54Z","timestamp":1760125674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/11\/4521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["molecules28114521"],"URL":"https:\/\/doi.org\/10.3390\/molecules28114521","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}